WallStSmart
TNYA

Tenaya Therapeutics Inc

NASDAQ: TNYA · HEALTHCARE · BIOTECHNOLOGY

$1.00
-5.70% today

Updated 2026-06-05

Market cap
$171.43M
P/E ratio
P/S ratio
761.91x
EPS (TTM)
$-0.44
Dividend yield
52W range
$1 – $2
Volume
4.0M

Tenaya Therapeutics Inc (TNYA) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-24.10M$-35.45M$-60.81M$-104.42M$-102.07M$-90.50M$-68.26M
Capital expenditures$2.93M$9.76M$25.12M$20.63M$1.24M$1.02M$618000.00
Depreciation$1.99M$2.48M$2.96M$6.47M$8.69M$8.47M
Stock-based comp$414000.00$741000.00$2.95M$11.47M$15.31M$16.50M$13.05M
Free cash flow$-27.02M$-45.21M$-85.93M$-125.05M$-103.31M$-91.53M$-68.88M
Investing cash flow$-5.58M$-7.01M$-238.56M$83.65M$48.72M$1.13M
Financing cash flow$30.51M$147.27M$208.97M$77.77M$4.05M$47.75M
Dividends paid
Share repurchases
Debt repayment
Net change in cash$-90.41M$56.99M

Frequently asked questions

What is Tenaya Therapeutics Inc's revenue?

Tenaya Therapeutics Inc's trailing twelve-month revenue is $225000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does TNYA generate?

TNYA produced $-68.88M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TNYA's balance sheet healthy?

TNYA holds $100.55M in cash and equivalents against — in long-term debt, on $123.27M of shareholder equity. That debt is best read against the cash flow the business throws off each year.